Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Prothena Corporation plcNASDAQ: PRTA

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $184K fell 17.5% year over year, behind the +258.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 15.6% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.

Context

  • Depreciation & amortization amounted to 9.2% of revenue in FY2025, up 8.6 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -17.5% toward the trailing-twelve-month pace of +258.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$184K-15.6% QoQ
Last fiscal yearDec 2025
$895K+0.2% YoY
LTMMar 2026
$856K+258.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.5%——
1 year+0.2%——
3-year CAGR+6.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
895K USD
Year-over-year change
+0.2%
4-year CAGR
-5.3%

Depreciation & Amortization vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +258.2% is the 2nd highest of 8, against a peer median of +13.2%.
  • Depreciation & amortization amounts to 1.5% of revenue for PRTA, versus a peer median of 69.9%.
PRTA Competitors
Depreciation & Amortization for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$842.9M USD+13.2%+14.6%8.5%
DNLIDenali Therapeutics Inc.LTM Jun 2026$13.14M USD+17.5%+12.6%364.7%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.5M CHF+15.5%+0.4%69.9%
ANNXAnnexon, Inc.LTM Mar 2026$2.17M USD+0.9%+0.9%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$880K USD+391.6%——
PRTAProthena Corporation plcLTM Mar 2026$856K USD+258.2%+6.4%1.5%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$251K USD-0.8%-1.0%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$59K USD-90.6%-29.5%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 USD———
PMNProMIS Neurosciences, Inc.LTM Jun 2026$0 USD———
Peer median (excluding PRTA) —+13.2%+0.7%69.9%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Depreciation & Amortization1.12M744K928K893K895K
Deferred Income Tax4.57M(11.13M)(15.69M)(9.35M)43.24M
Stock-Based Compensation24.66M31.32M40.91M45.96M37.64M
Change in Working Capital(10.4M)(18.8M)(20.53M)(67.94M)(4.17M)
Accounts Receivables15K0(5.16M)5.16M0
Inventory00(8.9M)00
Accounts Payables(492K)11.87M22.86M(18.3M)(15.78M)
Other Working Capital(9.93M)(30.67M)(29.33M)(54.8M)11.6M
Other Non-Cash Items5.69M6M7.5M2.69M2.91M
Operating Cash Flow92.61M(108.82M)(133.91M)(150.05M)(163.58M)
Capital Expenditures(575K)(464K)(2.81M)(298K)(138K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0037K00
Investing Cash Flow(575K)(464K)(2.77M)(298K)(138K)
Debt Repayment00000
Common Stock Issued174.79M223.62M23.58M0(139K)
Common Stock Repurchased000(353K)0
Dividends Paid00000
Other Financing Activities15.54M17.84M21.52M1.91M0
Financing Cash Flow190.33M241.46M45.1M1.55M(139K)
Effect of Forex Changes00000
Net Change in Cash282.36M132.17M(91.58M)(148.79M)(163.86M)
Free Cash Flow92.03M(109.29M)(136.72M)(150.35M)(163.72M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.